Biopharmaceutical company Advicenne announces that ADV7103, its proprietary drug, has been granted orphan drug status (ODD) by the US FDA for the treatment of cystinuria in the USA.

Cystinuria is a genetic disease characterized by an accumulation of the amino acid cystine in the kidneys and bladder, leading to complications that can ultimately lead to chronic renal failure.

The treatment of this condition by simplified alkalinization is a major unmet medical need and represents a very significant potential market, with over 30,000 patients in the United States", emphasizes CEO Didier Laurens.

Copyright (c) 2024 CercleFinance.com. All rights reserved.